ReviewCurrent opinion in supportive and palliative care2016
Neuroleptics in the management of delirium in patients with advanced cancer.
Review in Current opinion in supportive and palliative care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04750395 (Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication.Cancer · 2021Trial
- Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.The Lancet. Oncology · 2020Trial
- Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.The oncologist · 2020Trial
- Trial
- Trial
- Integrating Physiatry and Palliative Care in Outpatient Oncology: A Clinical Framework for Bidirectional Referral and Co-Management.Current oncology (Toronto, Ont.) · 2026Review
- Opioid use and subsequent delirium risk in patients with advanced cancer in palliative care: a multicenter registry study.Scientific reports · 2024Article
- Palliative Sedation in End-of-Life Patients in Eastern Asia: A Narrative Review.Cancer research and treatment · 2022Review
- Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium.Journal of palliative medicine · 2022Observational
- Chlorpromazine as Treatment for Refractory Agitation Associated with Pediatric Delirium.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication.Current opinion in supportive and palliative care · 2018Review
- Palliative Sedation for the Terminally Ill Patient.CNS drugs · 2018Review
- Updates in palliative care - recent advancements in the pharmacological management of symptoms.Clinical medicine (London, England) · 2018Review
- Bispectral Index monitoring in cancer patients undergoing palliative sedation: a preliminary report.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Observational
- Neuroleptics for Delirium: More Research Is Needed.JAMA internal medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewDelirium is the most common and distressing neuropsychiatric syndrome in cancer patients. Few evidence-based treatment options are available due to the paucity of high quality of studies. In this review, we shall examine the literature on the use of neuroleptics to treat delirium in patients with advanced cancer. Specifically, we will discuss the randomized controlled trials that examined neuroleptics in the front line setting, and studies that explore second-line options for patients with persistent agitation. RECENT
findingsContemporary management of delirium includes identification and management of any potentially reversible causes, coupled with nonpharmacological approaches. For patients who do not respond adequately to these measures, pharmacologic measures may be required. Haloperidol is often recommended as the first-line treatment option, and other neuroleptics such as olanzapine, risperidone, and quetiapine represent potential alternatives. For patients with persistent delirium despite first-line neuroleptics, the treatment strategies include escalating the dose of the same neuroleptic, rotation to another neuroleptic, or combination therapy (i.e., the addition of a second neuroleptic or other agent). We will discuss the advantages and disadvantages of each approach, and the available evidence to support each strategy. SUMMARY: Adequately powered, randomized trials involving proper control interventions are urgently needed to define the optimal treatment strategies for delirium in the oncology setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.